An autophagosome-based therapeutic vaccine for HBV infection: a preclinical evaluation by Meng Xue et al.
Xue et al. Journal of Translational Medicine  (2014) 12:361 
DOI 10.1186/s12967-014-0361-4RESEARCH Open AccessAn autophagosome-based therapeutic vaccine for
HBV infection: a preclinical evaluation
Meng Xue1†, Fei Fan1†, Lei Ding1†, Jingyu Liu1, Shu Su1, Pengfei Yin1, Meng Cao1, Wei Zhao2, Hong-ming Hu2,3*
and Lixin Wang1,2*Abstract
Background: For more than 240 million chronic HBV carriers worldwide, effective therapeutic HBV vaccines are
urgently needed. Recently, we demonstrated that autophagosomes were efficient antigens carriers and capable to
cross-prime robust T-cell responses and mediate regression of multiple established tumors. Here we tested whether
autophagosomes derived from HBV expressing cells could also function as a therapeutic vaccine.
Methods: We generated an autophagosome-based HBV vaccine from HBV-expressing hepatoma cells and examined
its ability to induce polyvalent anti-HBV T-cell responses and therapeutic efficacy in mouse models that mimic acute
and chronic HBV infection in human.
Results: When compared to the vaccine based on recombinant HBsAg, autophagosome-based HBV vaccine
cross-primed multi-specific anti-HBV T-cell responses and significantly reduced HBV replication and HBcAg expression
in livers of both acute and chronic mouse models. Therapeutic effect of this HBV vaccine depended on anti-HBV
CD8+ effector T cells and associated with increased HBsAg and HBcAg specific IFN-γ producing T cells in the
chronic mouse model.
Conclusions: These results indicated that autophagosome-based HBV vaccine could effectively suppress the
HBV replication, clear the HBV infected hepatocytes, and break the HBV tolerance in mouse model. The potential
clinical application of autophagosome-based HBV vaccine is discussed.
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Chronic hepatitis B virus (HBV) infection remains a major
health problem worldwide as it often causes many serious
complications like hepatic cirrhosis and hepatocellular
carcinoma [1]. The current treatment for chronic HBV
infection is primarily based on antiviral chemotherapy or
interferon therapy. Although these agents have improved
considerably over the last 10 years, they fail to eradicate
infection due to the persistence of HBV covalently closed
circular DNA (cccDNA) in hepatocytes and the emer-
gence of resistant viruses [2-5].* Correspondence: hhu@providence.org; lxwang@seu.edu.cn
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unless otherwise stated.Therapeutic vaccination is a promising strategy to control
chronic infection and delay the progression of diseases,
especially when used in combination with antivial chemo-
therapy. Unfortunately, therapeutic vaccination of chronic
HBV patients with HBsAg in combination with antiviral
chemotherapy did not show any superior efficacy over
chemotherapy alone [6]. Attempt to increase the thera-
peutic efficacy using HBsAg combined with anti-HBs
immunoglobulin only showed a minor improvement [7].
Similarly, a vaccination strategy using DNA prime and
protein boost also worked poorly in a recent randomized
clinical trial [8]. These rather disappointing results are
likely related to the fact that vaccination with the
HBsAg alone is insufficient and a strong, polyvalent,
and poly-functional CD8+ T-cell response against other
HBV antigen besides HBsAg is required for viral clear-
ance. Such a T-cell response was detected in subjects
with self-limited HBV infection, but it is exhausted andis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tion [9]. Thus, novel therapeutic vaccines are urgently
needed for the treatment of chronic HBV infection
[10]. Based on our current knowledge, an ideal HBV
therapeutic vaccine needs to be able to elicit a strong
and multi-specific T cell response, which is capable of
controlling HBV infection [11].
Recently, others and we have shown that autophagy
of tumor cells or virus-infected cells plays important
roles for the efficient cross-presentation of tumor and
viral antigens [12-16]. However, cross-presentation favors
abundant proteins with a long half-life and largely ignores
short-lived proteins. The efficiency of cross-presentation
of short-lived proteins could be greatly increased by indu-
cing autophagy via inhibition of proteasome-mediated
proteolysis. Consequently, autophagosomes containing
short-lived defective ribosomal products (DRiPs), which
we referred to as DRibbles, were found to be highly
effective therapeutic cancer vaccines in multiple mouse
cancer models [13-16]. Thus, it is generally accepted that
autophagy can promote both MHC class II and class I
restricted T-cell immune responses to either tumors or
infectious pathogens [12-16].
Based on above findings, we hypothesized that increased
autophagy of HBV expressing hepatoma cells [17] could
enhance the sequestration of multiple HBV antigens
into autophagosomes. These isolated autophagosome
(HBV+ DRibbles) can serve as a potent vaccine to stimu-
late polyvalent HBV-specific T-cell responses. To test this
hypothesis, we examined whether different autophagy
inducers could increase the production of DRibbles from
a HBV-producing hepatoma cells and further investigated
whether HBV+ DRibbles vaccine could induce polyvalent
anti-HBV immune responses and reduce ‘HBV infection’
in a mouse model [18].Materials and methods
Ethics statement
All experimental protocols were approved by the Institu-
tional Animal Care and Use Committee of Southeast
University.Mice, cell lines and reagents
C57BL/6 female mice were purchased from the Com-
parative Medicine Center, Yangzhou University. All mice
were bred and maintained in specific pathogen-free con-
ditions. HepG2.2.15 and HepG2 cell lines were gifts
from Dr. Jianqiong Zhang (Medical School of Southeast
University, China). All the cells were cultured in complete
medium made of DMEM or RPMI 1640 (Gibco, USA)
supplemented with 10% heat-inactivated FCS (Hyclone,
USA), 100 U/ml penicillin, 0.1 mg/ml streptomycin (Beyo-
time Institute of Biotechnology, China).HBV infection model
Naïve C57BL/6 mice (female, 6–8 weeks old) were injected
with 10 μg of pAAV/HBV1.2 plasmid DNA (containing
the HBV full-length genomic DNA) via the hydrodynamic
injection as described [18].
Preparation of HBV+ DRibbles or HBV− DRibbles
HepG2.2.15 cells containing transfected HBV full-length
DNA [17] or HepG2 cells were treated with 200 nmol/L
Bortizomib (Millennium pharmaceuticals, USA) alone or
in combination with 100 nmol/L Rapamycin (Enzo Life
Sciences, China) or 30 mmol/L NH4Cl for 18 h, DRib-
bles containing autophagosomes were prepared from the
culture media as described [13,14]. Morphology analysis
of HBV+ DRibbles was done under transmission electron
microscopy. HBsAg in HepG2.2.15 cell lysates was
detected by western blot analysis using anti-HBsAg anti-
body (Santa Cruz, Biotechnology, Inc., USA). LC3 in
both HepG2.2.15 cell lysates and HBV+ DRibbles was
determined by western blot analysis using the polyclonal
LC3B antibody (Cell Signal Technology, USA,1:1000),
the HRP-labeled goat anti-rabbit IgG secondary antibody
(1:5000) and a chemiluminescence kit (Multisciences
Biotech Co., Ltd., China). Levels of HBsAg and HBeAg
in HBV+ DRibbles were measured by ELISA (Shanghai
Kehua Bioengineering Co., Ltd., China).
Measurement of immune responses induced by
vaccination with HBV+ DRibbles
C57BL/6 mice were immunized with different doses of
HBV+ DRibbles or HBV− DRibbles (100, 30, 10 μg total
protein per mouse) or PBS via intranodal injection. Seven
days later, 2 × 105 lymphocytes per well were harvested and
re-stimulated with HBV antigens or peptides (HBc129-140:
PPAYRPPNAPIL; HBs190-197: VWLSVIWM) (China-
Peptides Co., Ltd., China) for 24 h. The number of
IFN-γ producing cells was detected by ELISPOT assay
(Laizee Biotech Co., Ltd., China).
To determine whether HBV+ DRibbles elicited cell
response and killed HBV infected hepatocytes, lympho-
cytes were harvested from HBV+ DRibbles vaccinated
mice at day 7 and used as effector T cells; hepatocytes
were collected from mice injected with pAAV/HBV1.2
plasmid DNA as the HBV-expressing target cells. Lym-
phocytes (2 × 106/well) were co-incubated with target
cells (2 × 104/well). The supernatants were collected for
detection of AST by clinical chemistry analyzer after
24 h or for detection of IFN-γ by ELISA (eBioscience,
USA) after 72 h.
Anti-HBV effect of vaccination with HBV+ DRibbles
C57BL/6 mice were immunized with HBV+ DRibbles,
HBV− DRibbles or PBS via intranodal injection as described
above. Seven days later, 10 μg of pAAV/HBV1.2 plasmid
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collected at day 14 for detection of HBeAg by ELISA and
HBV genomic DNA with real-time PCR. Liver tissues were
collected and embedded in paraffin. Intracellular HBcAg
expression was detected by immunohistochemical staining
with the rabbit anti-HBcAg antibody (1:100) using two-step
method (Zhongshan Goldenbridge Biotechnology Co., Ltd.,
China). Percentages of HBcAg+ hepatocytes were calculated
by counting at least 500 cells in five vision fields by two
investigators for each sample.
Depletion of CD4+ and CD8+ T cell subsets in vivo
Mice were vaccinated with 30 μg HBV+ DRibbles or PBS
as above mentioned. On day 7, after injection of pAAV/
HBV1.2 DNA into the mice, 200 μg anti-CD4 mAb
(clone GK1.5, rat IgG2b) or/and 20 μg anti-CD8 mAb
(clone 2.43, rat IgG2b) were administered intraperitoneally,
and the depleted condition was maintained by repeated
injections of the monoclonal antibody every 3 days for total
of 3 injections. At day 14, HBeAg level and HBV DNA copy
number in the serum samples and intrahepatic HBcAg
expression in liver tissues were detected as described above.
Therapeutic vaccination experiments
C57BL/6 mice were injected hydrodynamically with
pAAV/HBV1.2 plasmid DNA and were vaccinated with
30 μg HBV+ DRibbles, 2 μg HBsAg with Al(OH)3 adjuvant
(Center for Disease Control of Jiangsu Province, China)
or PBS via intranodal injection 2 days later. Then, two
intramuscular boost injections (2 μg of HBsAg with Al
(OH)3 adjuvant or 30 μg of HBV
+ DRibbles with αAl2O3
nanoparticles adjuvant [19]) were performed on day 5
and 7. The lymphocytes were isolated 7 days after first
vaccination and re-stimulated with recombinant HBV
antigens and peptides as described. The number of IFN-γ
producing cells in 2 × 105 lymphocytes was detected by
ELISPOT. The serum samples were collected on day 7
and 14 after first vaccination for measurement of ALT,
AST, HBeAg , HBsAg, HBV DNA. The serum anti-HBsAg
antibodies were detected by ELISA on day 14 after first
vaccination. Liver tissues were collected on day 14 after
first immunization for detection of percentage of HBcAg+
hepatocytes as mentioned above. The liver sections were
stained with hematoxylin-eosin.
Adoptive transfer experiments
C57BL/6 mice were injected hydrodynamically with 10 μg
pAAV/HBV1.2 plasmid DNA to establish HBV tolerant
mice [18]. Sixty days later, tolerance toward HBsAg was
noted in HBV carrier mice. The HBsAg tolerant mice were
selected and then immunized with above HBV+ DRibbles
or HBsAg or PBS on day 61, respectively. Two intramus-
cular boost injections with the same dose of vaccines as
above were done on day 63 and 65. Lymphocytes wereharvested from the immunized mice and re-stimulated
with HBV antigens and peptides on day 67 as described.
The number of IFN-γ producing cells in 2 × 105 lympho-
cytes was measured by ELISPOT. In addition, at day 68, a
total of 1 × 108 lymphocytes from vaccinated HBsAg toler-
ant mice were adoptive transferred intravenously into each
of the new set of 60-day HBV carrier mice. Serum samples
were collected on day 3, 7, 14 and 21 after adoptive
transfer for detection of ALT, AST, HBsAg and HBV
DNA. The serum anti-HBsAg antibodies were measured
by ELISA on day 21 after adoptive transfer. Liver tissues
were collected on day 21 for detection of percentage of
HBcAg+ hepatocytes. The liver sections were stained with
hematoxylin-eosin.Statistical analysis
One-way ANOVA or two-way ANOVN with Bonferronic
post test and the two-tails paired t test were performed
using GraphPad Prism5.0, (GraphPad Software Inc., San
Diego, CA). A P value of <0.05 was considered statistically
significant.Results
DRibbles are capable to encapsulate multiple HBV antigens
First, we investigated whether DRibbles contained HBV
antigens when they were prepared from HepG2.2.15
cells that were transfected with HBV DNA and stably
expressed HBV antigens. HepG2.2.15 cells were treated
with Bortizomib, Rapamycin or NH4Cl at the pre-
determined optimal concentrations; whole cell lysates
and DRibbles were prepared as described and subjected
to western blot analysis using antibodies against HBsAg
and LC3 [13]. The major HBsAg protein did not differ
after different treatments (Figure 1A). Interestingly,
Bortizomib treatment led to appearance of HBsAg of
lower molecular weight than full-length products and
addition of NH4Cl further increased the appearance of
these bands (Figure 1A). Because these bands appear only
after inhibition of proteasome function, they are most
likely representatives of DRiPs of HBsAg. No significant
conversion of LC3 protein was found in HepG2.2.15 cells
treated with Bortizomib, Rapamycin, or combination of
both. However, accumulation of LC3-II in cell lysates
and predominant LC3-II in the DRibbles was found
when NH4Cl was included in addition to Bortizomib
and Rapamycin treatment (Figure 1B,C) [20,21]. Trans-
mission electron microscopy analysis showed that
DRibbles had a double-membrane structure and their
size was ranged from 100 to 1000 nm (Figure 1D).
ELISA analysis showed that the amount of HBsAg and
HBeAg in the DRibbles were doubled when all three
drugs were combined (Figure 1E,F). These data indi-
cated that combination of Bortizomib, Rapamycin, and
Figure 1 Detection of HBV antigens in DRibbles. HepG2.2.15 cells were treated without (lane 1) or with Bortizomib alone (lane 2), Rapamycin
alone (lane 3), Bortizomib plus Rapamycin (lane 4) or combination of Bortizomib, Rapamycin and NH4Cl (lane 5) for 18 h. Lysates were prepared
for the HBsAg and the LC3 conversion analysis by western blot (A,B). The HBV+ DRibbles prepared from both untreated and treated cells were analyzed
for LC-3-I and LC-3-II by western blot analysis (C). Anti-β-actin antibody was included as a sample loading control. Morphology of DRibbles was
observed by transmission electron microscopy (D). The amount of HBeAg (E) and HBsAg (F) in the DRibbles were quantified by ELISA.
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and HBeAg into autophagosomes.
HBV+ DRibbles elicit protective HBV-specific immune
responses
To determine the optimal dose of HBV+ DRibbles to elicit
HBV antigen-specific immune responses, different doses
of HBV+ DRibbles or HBV− DRibbles were administrated
into the lymph nodes of naïve C57BL/6 mice (Figure 2A).
We chose the intranodal injection of DRibbles as the
route of antigen delivery because our preliminary experi-
ments indicated direct injection of DRibbles into lymph
nodes resulted the greatest DCs recruitment and T-cell
activation. ELISPOT assay revealed that spleen and lymph
nodes from mice injected with 30 μg of HBV+ DRibbles
contained the highest number of HBsAg or HBcAg
specific IFN-γ producing cells (Figure 2B). Injection of
10 μg of DRibbles was insufficient, while 100 μg showed a
high-dose suppression. To further determine whether
immunogenicity and xenoreaction of DRibbles derived
from human HepG2 cells (HBV− DRibbles) lead to immune
reactive to HBV antigens, C57BL/6 mice were also immu-
nized with titrated amount of HBV− DRibbles. Noticeably,
lymphocytes from 30 μg HBV+ DRibbles vaccinated micegenerated much higher number of IFN-γ producing cells
than that from 30 μg HBV− DRibbles vaccinated mice when
re-stimulated with either HBV antigens or HBV peptides
(Figure 2C). Thus, HBV+ DRibbles effectively induced both
HBsAg- and HBcAg-specific and HBc129–140, HBs190–197-
specific cell-mediated immune responses. Thirty μg total
proteins seem to be optimal dose for the HBV+ DRibbles
vaccine administrated via intranodal injection in mice.
To evaluate whether 30 μg of HBV+ DRibbles could
protect immunized mice from establishment of HBV
replication via HBV plasmid DNA injection, C57BL/6
mice were vaccinated with PBS or different doses of
HBV+ DRibbles or HBV− DRibbles and were challenged
with hydrodynamic injection of HBV DNA 7 days later
(Figure 2A). Serum HBV DNA and HBeAg levels were
used as the indicators of viral replication and production.
Mice immunized with 30 μg HBV+ DRibbles, but not
naïve mice or mice immunized with HBV− DRibbles and
other doses of HBV+ DRibbles, were protected from HBV
DNA challenge (Figure 2D,E). To further corroborate this
data, liver tissues were harvested and intrahepatic express-
ing of HBcAg was quantified by immunohistochemical
staining. Similar to the results of HBeAg and HBV DNA,
the percentage of HBcAg+ hepatocytes in the mice
Figure 2 HBV+ DRibbles elicited HBV-specific protective immune response. The schematic diagram outlines the experiment protocol (A).
The optimal dose of HBV+ DRibbles was determined by ELISPOT assay (n = 3). Lymphocytes from mice received HBV+ DRibbles generated a high
number of IFN-γ secreting cells in 2 × 105 lymphocytes (B,C). Vaccinated mice were injected hydrodynamically with 10 μg of HBV plasmid DNA
(n = 5) 7 days later. The serum HBV DNA (D) and HBeAg (E) was determined by real-time PCR and ELISA. Intrahepatic HBcAg was visualized by
immunohistochemical staining (×200) (F). Results represent three independent experiments.
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lower than control mice injected with HBV− DRibbles or
PBS (Figure 2F). Moreover, there were no significant dif-
ference between the mice immunized with HBV− DRib-
bles and those with PBS. Our results showed that HBV+
DRibbles vaccination, but not HBV− DRibbles, could ef-
fectively reduce HBV replication and expression.
CD8+ T cells induced by HBV+ DRibbles mediated
suppression of HBV replication
To investigate the requirement of CD4+ helper T cells or
CD8+ effector T cells for the control of HBV replication,
anti-CD4 mAb or/and anti-CD8 mAb were adminis-
trated intraperitoneally on the same day as HBV DNA
injection into HBV+ DRibbles-vaccinated mice. The mono-
clonal antibodies were injected repeatedly every 3 days
to maintain the depleted condition (Figure 3A). Results
showed again that non-depleted mice immunized with
HBV+ DRibbles had a reduced level of serum HBeAg
(Figure 3B), DNA copy number (Figure 3C) and HBcAg+
expressing hepatocytes (Figure 3D). The DNA copy
number in mice depleted of CD8+ effector T cells were not
significantly different from that of control non-immunized
naïve mice. Depletion of both CD4+ and CD8+ effector T
cells did not further increase the serum HBeAg or DNA
copy number beyond that of mice received anti-CD8
antibody (Figure 3B,C). These data indicated the criticalFigure 3 CD8+ T cells mediated protection induced by HBV+ DRibbles
were injected hydrodynamically with HBV plasmid DNA 7 days after vaccin
anti-CD4 mAb, anti-CD8 mAb or anti-CD4 mAb plus anti-CD8 mAb, respec
detected by ELISA and real-time PCR. Intrahepatic HBcAg was visualized by
vaccinated mice (n = 3) were co-incubated with target cells (the effector to
were assayed by ELISA and by clinical chemistry analyzer. These experimenrequirement for priming of anti-HBV CD8+ T cells for
viral clearance.
To examine the effect function of T cells from HBV+
DRibbles vaccinated mice, lymphocytes from HBV+ DRib-
bles immunized mice were co-cultured with hepatocytes
isolated from HBV DNA injected mice (Figure 3A).
Results showed that significantly higher levels of IFN-γ
were detected in the culture supernatants when effector T
cells were incubated with HBV-expressing hepatocytes
than control hepatocytes (Figure 3E). Moreover, AST
detection showed that significantly higher levels of AST
enzyme release were found in HBV-expressing hepato-
cytes than control hepatocytes (Figure 3F). These data
suggested that HBV+ DRibbles elicited strong cell immune
response that was capable to produce IFN-γ and kill
HBV-expressing hepatocytes isolated from mice in vitro.
Vaccination with HBV+ DRibbles was effective against
acute HBV infection
To test whether HBV+ DRibbles could be used as thera-
peutic vaccine in a setting that mimicking acute HBV
infection and to compare the efficacy of HBV+ DRibbles
with recombinant protein HBsAg vaccine, C57BL/6 mice
were first injected with pAAV/HBV1.2 DNA to establish
HBV acute infection and then were immunized with HBV+
DRibbles or HBsAg or PBS 2 days later. Two times boost
immunizations were administrated by intramuscular. The schematic diagram outlines the experiment protocol (A). Mice
ation and immediately subjected to intraperitoneal injection of PBS,
tively (n = 5) (B-D). The serum HBeAg (B) and HBV DNA (C) were
immunohistochemistry (×200) (D). Lymphocytes from HBV+ DRibbles
target ratio was 100:1) before the supernatant IFN-γ (E) and AST (F)
ts were repeated three times with comparable results.
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adjuvant was used in our HBV+ DRibbles vaccine due to
its ability to greatly increase the efficiency of cross-
presentation and anti-tumor response of cancer vaccines
[19] (Figure 4A).
Consistent with previous results, lymphocytes harvested
from HBV+ DRibbles-immunized mice generated a signifi-
cantly higher number of IFN-γ producing cells than that
from PBS or HBsAg immunized mice when re-stimulation
ex vivo with HBV antigens or peptides (Figure 4B,C,D).
The serum levels of HBeAg in HBV+ DRibbles-immunized
mice were greatly reduced as compared to both HBsAg
vaccinated mice and control mice, and no statistical differ-
ence was found between HBsAg vaccinated mice and the
control mice (Figure 4E). We found that the levels of
serum HBsAg in HBV+ DRibbles immunized mice were
significantly lower than that of control mice withoutFigure 4 Therapeutic efficacy of HBV+ DRibbles vaccine. The schemati
acute HBV-infected mice received HBV+ DRibbles or HBsAg or PBS were iso
of IFN-γ producing cells in 2 × 105 lymphocytes was detected as described (n
the percentage of HBcAg+ hepatocytes (H) of immunized mice or control mi
repeated three times.vaccination, but much higher than that of HBsAg im-
munized mice (Figure 4F). Detection of anti-HBsAg
antibody in serum from immunized mice showed that
HBsAg vaccination induced significantly higher levels
of anti-HBs compared with HBV+ DRibbles vaccination
(Additional file 1: Figure S1A). Serum anti-HBsAg
antibody was detected only in two of six mice received
HBV+ DRibbles immunization. Most importantly, HBV
DNA copy number in the sera (Figure 4G) and per-
centage of HBcAg+ hepatocytes in the liver tissues
(Figure 4H) in HBV+ DRibbles-immunized mice were
greatly reduced as compared to control mice received
either no vaccine or HBsAg vaccine. In addition, sera
ALT and AST levels were determined and appeared not
to be influenced by the vaccinations (Additional file 1:
Figure S1B,C) and the livers from HBV+ DRibbles vac-
cinated mice showed normal architecture and a mildc diagram outlines the experiment protocol (A). Lymphocytes from the
lated and re-stimulated with HBV antigens or peptides and the number
= 3) (B-D). Serum HBeAg (E), HBsAg (F), HBV DNA copy number (G) and
ce were measured as mentioned above (n = 6). These experiments were
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Thus far, our studies indicated that HBV+ DRibbles
were more effectively than HBsAg, at eliciting therapeutic
cell-mediated immune responses in an acute HBV
infection mouse model established by hydrodynamic in-
jection of HBV plasmid DNA and did not cause obvious
liver damage.Figure 5 Immunized lymphocytes transfer adoptive immunity agains
HBV+ DRibbles elicited IFN-γ producing cells in 2 × 105 lymphocytes agains
lymphocytes were adoptively transferred intravenously into each of the ne
serum samples were collected for detection of HBsAg (D), HBV DNA copy
hepatocytes were determined as described (n = 4) (F). These experiments wDRibbles induced therapeutic T cells and break tolerance
in HBsAg tolerant mice
Next, we investigated whether HBV+ DRibbles immu-
nization could induce therapeutic immunity and break
tolerance in a HBV tolerant mouse model. HBsAg tolerant
mice were established by hydrodynamic injection of HBV
DNA as described [18] (Additional file 2: Figure S2A).t HBV. The schematic diagram outlines the experiment protocol (A).
t multiple HBV antigens or peptides (n = 3) (B,C). A total of 1 × 108
w ‘HBV tolerant’ mouse. At day 7, 14 and 21 after adoptive transfer,
number (E). The liver tissues were harvested on day 21 and HBcAg+
ere repeated three times with comparable results.
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positive were inoculated with HBV+ DRibbles or HBsAg
or PBS. Seven days after first immunization, lymphocytes
were harvested and re-stimulated by HBV antigens and
peptides (Figure 5A). The data showed that HBV+
DRibbles, but not HBsAg, induced HBV-specific IFN-γ
spot-forming cells when re-stimulated ex vivo with recom-
binant HBsAg or HBcAg proteins or MHC I binding
peptides derived from these antigens (Figure 5B,C).
Since the level of antibody response in DRibbles-vaccinated
mice in the acute ‘HBV infected’ mouse model was very
low, we decided to examine whether immune cells rather
than serum conferred the control of HBV replication
using an adoptive transfer model. To that end, immunized
lymphocytes harvested from spleens and lymph nodes of
immunized mice were adoptively transferred to a new set
of HBsAg tolerant mice that received HBV DNA injection
60 days before. The levels of serum HBsAg, HBV DNA
(Figure 5D,E) were markedly decreased and HBcAg+
hepatic cells were greatly reduced in HBsAg tolerant mice
after adoptive transfer of lymphocytes from HBV+ DRib-
bles vaccinated mice (Figure 5F). In contrast, the mice
received lymphocytes from HBsAg vaccinated mice did
not exhibit any measurable effect. Interestingly, anti-HBsAg
antibodies were detected in mice received lymphocytes
from DRibbles, but not PBS and HBsAg immunized mice
(Additional file 2: Figure S2B). Furthermore, the serum
ALT and AST levels in the mice received lymphocytes from
HBV+ DRibbles immunized mice were similar to that of re-
ceived lymphocytes from non-immunized control mice
(Additional file 3: Figure S3A,B) and the livers of the
mice receiving HBV+ DRibbles-treated lymphocytes showed
normal architecture with a mild inflammatory infiltrates
(Additional file 3: Figure S3C). The results indicated
that HBV+ DRibbles were able to reverse the tolerance
to HBsAg and induce therapeutic T cells, and these
HBV-specific T cells adoptively transferred into HBsAg
tolerant mice did not cause severe liver damage.
Discussion
Previously, others and we demonstrated that autophagy of
antigen donor cells plays a critical role in the cross-
presentation of tumor associated antigens or viral antigens
[12-16]. In this study, we investigated whether multiple
HBV antigens could be accumulated in DRibbles by
treatment of HBV expressing cells with various agents
modulating proteasome function and autophagy mediated
protein degradation [13-16]. In addition to the accumu-
lation of HBV antigens, DRibbles also contained specific
ligands and ‘build-in adjuvant’ could stimulate specific
subsets of DCs to efficiently cross-present antigens. It is
likely that membrane-structured DRibbles might include
innate adjuvant activity for activation of innate and induc-
tion of antigen-specific CD8+ T cell response [14].The development of candidate therapeutic vaccines for
patients with chronic HBV infection is greatly hampered
by the lack of clinical relevant mouse models. Fortunately,
when HBV DNA is artificially introduced into mouse
hepatocytes, HBV expression and replication can be
established. Different methodology has been exploited
to introduce HBV genome into adult murine hepatocytes
[18,22-24]. Hydrodynamic injection of plasmid DNA typ-
ically results in about 10% of HBV-expressing hepatocytes,
long-term HBV expression and immunological tolerance
similar to chronic human HBV carriers [18,23]. Hydro-
dynamic injection of HBV DNA of mice is proven to be a
good murine model for studies of HBV replication and
immune responses. Here, we employed this model to
develop a novel HBV therapeutic vaccine based on autop-
hagosomes derived from HBV expressing hepatoma cells.
The HBV+ DRibbles produced from a HBV expressing
cell line were effective as a prophylactic vaccine or a
therapeutic vaccine to treat mice with established HBV
replication. Our results showed that HBV+ DRibbles could
prime both HBsAg and HBcAg-specific immune responses
and the IFN-γ producing and CD8+ T cells played domin-
ant roles in the HBV clearance. It is previously reported
that an impaired HBcAg-specific immunity is the major
cause for HBV persistence after the hydrodynamic injection
of HBV DNA [18]. HBcAg-specific immunity plays a
critical role in the clearance of HBV and HBV antigen-
harboring hepatocytes [25,26]. As expected, HBV+ DRib-
bles was able to reduce HBV replication in vivo. Whether
HBV+ DRibbles could also induce immune responses to
other HBV antigens, such as X protein and HBV polymerase
remains to be determined. The HBxAg is of particularly rele-
vant antigen as it is required for productive HBV infection
and replication [27]. HBxAg is a short-lived protein and
rapidly degraded by proteasomes [28] and X-protein spe-
cific T cells are less likely impaired or exhausted in pa-
tients with chronic HBV infection.
Previous studies have demonstrated that both CD4+ T
cells and CD8+ T cells are required for elimination of
HBV from the liver during natural infection [29,30]. As
helper T cells for both B-cell and CTL responses against
HBV, CD4+ T cells serve as master regulators of the
adaptive immune response to HBV. B-cells produce crit-
ical neutralization antibodies that prevent viral entry and
CD8+ T cells are the key cellular effectors mediating
HBV clearance by killing of HBV-infected hepatocytes.
We found that HBV clearance in our model primarily
depended on CD8+ T cells and CD4+ T cells was less
important. The predominant dependence on CD8+ T
cells is probably because hydrodynamic injection of
HBV DNA effectively bypassed the viral entry step.
However, we did not examine whether HBV+ DRibbles
could activate other innate immune components such as
NK and NKT cells, as their contributions in the induction
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efficacy could not be ignored [31-33].
It is known that strong, multi-antigen specific, HBV-
specific T cell responses in particular mediated by CD8+
cells are correlated with HBV control and resolution
[29,30] and the neutralization antibodies could be critical
important acting together with CTL to effective control
and eliminate chronic HBV infection. During treatment
of acute ‘HBV infection’ of our mouse model, HBV+
DRibbles vaccine was capable of eliciting strong and
multi-specific T cell responses. Compared to HBV+ DRib-
bles vaccination, HBsAg immunization could not generate
HBcAg- and HBsAg-specific and peptides-specific cell
response; however, it was able to induce humoral response.
Interestingly, some of the HBV+ DRibbles treated mice did
produce anti-HBsAg antibodies, although the mean level
was lower than that induced by HBsAg at the indicated
time points. Importantly, when lymphocytes from immu-
nized HBV tolerant mice adoptively transferred into new
set of tolerant mice, the suppression of HBV DNA replica-
tion and the clearance of HBcAg+ hepatocytes were only
detected in HBV+ DRibbles vaccinated group. Also, anti-
HBsAg antibody response could be induced in some of the
tolerant mice after adoptively transferred of lymphocytes
from HBV+ DRibbles vaccinated mice. It is consistent with
the notion that HBcAg-specific T cells support the anti-
HBsAg antibody response [18]. The anti-HBsAg antibodies
could also contribute to the neutralization of serum HBsAg,
and the virus control and elimination of HBV infected cells
required HBcAg-specific T cells.
α-Al2O3 nanoparticles, in contrast to traditional Alum
adjuvant, are capable to deliver antigen for very efficient
priming of CTLs and capable of boosting the anti-tumor
efficacy of tumor-derived autophagosomes [19]. Our data
demonstrated that HBV+ DRibbles mixed with α-Al2O3
nanoparticles could elicit an endogenous T-cell response
capable of eliminating established ‘HBV infection’. The
results suggested that HBV+ DRibbles vaccine together
with potent adjuvant was capable to elicit therapeutic
immune response and overcome HBV tolerance in our
mouse model. The recent identification of HBV receptor
makes it possible to generate authentic mouse model for
chronic HBV infection [34].
Furthermore, DRibbles vaccine strategy was developed
for cancer patients with terminal diseases [13-16], their
safety and efficacy are tested currently in phase I and II
clinical trials. A more stringent requirement for safety
needed to be taken into consideration if DRibbles derived
from a hepatocellular cell line will be tested in chronically
HBV-infected humans. DRibbles isolated from cell line
will unavoidably compose of cellular proteins in addition
to HBV antigens. We did not observe cross-reactivity with
normal cells when mice were vaccinated with DRibbles
derived from cancer cells or cultured normal kidney cellsand long term survival mice did not suffer noticeable
autoimmune diseases in preclinical studies (unpublished
data), but the potential long-term adverse effects of DRib-
bles vaccine in cancer patients are not known yet. Because
of the high probability of developing HCC in patients with
chronic HBV infection, the potential benefit of protection
against HCC induced by HBV+ DRibbles derived from
hepatocellular carcinoma cell line could outweigh the
minimal risk of increased autoimmunity.
Conclusions
Our results indicate that autophagosome-based vaccine
could induce multifaceted immune responses and target
T-cell mediated immune responses to many antigens of
pathogens, which are not efficiently elicited or rendered
tolerant during the natural course of infections. Thus,
our findings have important implications for the devel-
opment of therapeutic vaccines for the treatment of
chronic infections of HBV or other viruses.
Additional files
Additional file 1: Figure S1. Humoral response was induced in acute
HBV infection. The same experiment protocol was performed as Figure 4.
Serum samples were collected at day 14 after vaccination and anti-HBsAg
antibody was detected by ELISA (A). Serum ALT and AST levels were
measured on automated clinical chemistry analyzer at indicated time
points (B,C). The liver sections were stained with hematoxylin-eosin at
day 14 after vaccination (×400) (n = 6) (D).
Additional file 2: Figure S2. Tolerance toward HBsAg in HBV carrier mice.
Serum anti-HBsAg antibody in HBV carrier (n = 4) or naive C57BL/6 (n = 4) mice
after immunization with HBsAg vaccine (60 days after hydrodynamic injection
of pAAV/HBV1.2 or PBS, the same protocol of HBsAg vaccination as above) was
determined by ELISA at day 14 after vaccination (A). Humoral response was
detected in chronic HBV infection. The same experiment protocol was per-
formed as Figure 5. Serum samples were collected at day 21 after adoptive
transfer and anti-HBsAg antibody was assayed by ELISA (n = 4) (B).
Additional file 3: Figure S3. Serum ALT and AST levels were measured
on automated clinical chemistry analyzer at indicated time points (A,B).
The liver sections were stained with hematoxylin-Eosin at day 21 after
adoptive transfer (×400) (n = 4) (C).
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